Searching. Please wait…
1580
37
170
29264
4420
2603
347
391
Abstract: A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse.
Fuente: Cells , 2019, 8(11), 1432
Publisher: MDPI
Year of publication: 2019
No. of pages: 18
Publication type: Article
DOI: 10.3390/cells8111432
ISSN: 2073-4409
Publication Url: https://doi.org/10.3390/cells8111432
Consult in UCrea Read publication
MOGOLLÓN, PEDRO
DÍAZ TEJEDOR, ANDREA
ALGARÍN, ESPERANZA M.
PAÍNO, TERESA
GARAYOA, MERCEDES
ENRIQUE MARIA OCIO SAN MIGUEL
Back